title: Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer.
abstract: BACKGROUND
  We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients.
  
  
  METHODS
  Metformin 1,500 mg daily was administered to 35 nondiabetics with stage 0-III BC, body mass index (BMI) ≥ 25 kg/m(2). The primary endpoint was tumor proliferation change (i.e., ki-67). Tumor proliferation change was compared to untreated historical controls, matched by age, BMI, and stage.
  
  
  RESULTS
  There was no reduction in ln(ki-67) after metformin (p = .98) or compared to controls (p = .47). There was a significant reduction in BMI, cholesterol, and leptin.
  
  
  CONCLUSIONS
  Despite no proliferation changes, we observed reductions in other relevant biomarkers.
authors.affiliation: Department of Medicine, College of Physicians and Surgeons,1 Herbert Irving Comprehensive Cancer Center,2 Departments of Epidemiology and Biostatistics, Mailman School of Public Health,3 Department of Surgery, College of Physicians and Surgeons,4 Department of Medicine, Laboratory Irving Institute for Clinical and Translational Research, College of Physicians and Surgeons,5 Department of Pathology and Cell Biology,6 College of Physicians and Surgeons, Columbia University, New York, New York, USA.
authors.forename: Kevin
authors.initials: K
authors.lastname: Kalinsky
authors.forename: Katherine D
authors.initials: KD
authors.lastname: Crew
authors.forename: Susan
authors.initials: S
authors.lastname: Refice
authors.forename: Tong
authors.initials: T
authors.lastname: Xiao
authors.forename: Antai
authors.initials: A
authors.lastname: Wang
authors.forename: Sheldon M
authors.initials: SM
authors.lastname: Feldman
authors.forename: Bret
authors.initials: B
authors.lastname: Taback
authors.forename: Aqeel
authors.initials: A
authors.lastname: Ahmad
authors.forename: Serge
authors.initials: S
authors.lastname: Cremers
authors.forename: Hanina
authors.initials: H
authors.lastname: Hibshoosh
authors.forename: Matthew
authors.initials: M
authors.lastname: Maurer
authors.forename: Dawn L
authors.initials: DL
authors.lastname: Hershman
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000097:blood; D015992:Body Mass Index; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D049109:Cell Proliferation / Q000187:drug effects*; D017024:Chemotherapy, Adjuvant; D002784:Cholesterol / Q000097:blood; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D020738:Leptin / Q000097:blood; D008687:Metformin / Q000008:administration & dosage*; D008875:Middle Aged; D009367:Neoplasm Staging; D009519:New York City; D009765:Obesity / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D050177:Overweight / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D020738:Leptin; D008687:Metformin; D002784:Cholesterol